Clinical Trials: Country-Specific Clinical Trials

The Role of Veterans Affairs Hospitals in U.S. Clinical Research

Posted on digi By digi

Sponsors should: (1) engage VA research offices early; (2) prepare for extended contracting and IRB processes; (3) align trial designs with VA patient needs; (4) collaborate with academic affiliates for broader expertise; (5) validate use of VA data systems for regulatory purposes; (6) ensure staff training in FDA and VA-specific requirements; (7) maintain transparent communication with FDA; and (8) implement robust monitoring and CAPA systems for compliance.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Rare Disease Clinical Trials in India: Current Status

Posted on digi By digi

India lacks a specific “Orphan Drug Act” akin to the U.S. FDA or EU regulations, but steps have been taken through general frameworks such as the New Drugs and Clinical Trials Rules (NDCTR), 2019 and the National Policy for Rare Diseases (2021). Together, these provide a skeleton regulatory structure for rare disease research and drug development.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Clinical Trial Insurance Requirements in the UK

Posted on digi By digi

Insurance in UK clinical trials is a non-negotiable regulatory requirement. Sponsors, investigators, and NHS Trusts must demonstrate adequate coverage to protect participants and ensure compliance. By following a step-by-step approach—securing coverage early, maintaining valid certificates, and preparing for REC/MHRA scrutiny—sponsors can avoid regulatory delays and ensure trials proceed smoothly while safeguarding patient welfare.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Decentralized Trials in the EU: Current Status

Posted on digi By digi

DCT adoption in the EU must account for:

Pediatrics: Additional parental consent and child assent processes in eConsent models.
Rare Diseases: Decentralization helps overcome geographic dispersion of small patient populations.
Oncology: DCTs support frequent monitoring needs but must ensure robust adverse event reporting.
Advanced Therapies (ATMPs): Manufacturing and administration complexities limit decentralization potential.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Clinical Trial Supply Chain in Indian Settings

Posted on digi By digi

The New Drugs and Clinical Trials Rules (NDCTR), 2019 form the backbone of clinical trial regulation in India, including the provisions related to investigational product management. While there is no standalone “Clinical Trial Supply Chain” regulation, several clauses under NDCTR, GSR 227(E), and CDSCO’s guidance documents cover key areas of handling, storage, transportation, and accountability of IMPs.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Academic Clinical Trials in the United Kingdom

Posted on digi By digi

Academic clinical trials in the UK are central to advancing healthcare, generating evidence for NHS practice, and addressing unmet patient needs. By following a step-by-step process—securing funding, identifying sponsors, obtaining approvals, ensuring insurance, and preparing for MHRA inspections—academic investigators can run compliant, impactful trials. With NIHR and NHS infrastructure support, UK academia continues to play a leading role in global clinical research.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Expanded Access and Compassionate Use in the United States

Posted on digi By digi

Sponsors should: (1) establish SOPs for EA requests; (2) train investigators on FDA Form 3926; (3) predefine eligibility criteria; (4) maintain drug supply planning; (5) ensure IRB readiness; (6) document safety reporting rigorously; (7) communicate openly with patients; (8) align EA activities with global access programs; and (9) prepare inspection-ready records of all EA activities.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Brexit’s Impact on EU Clinical Trial Regulation

Posted on digi By digi

Brexit’s impact is particularly significant in:

Advanced Therapies (ATMPs): Dual oversight from EMA CAT and MHRA.
Rare Diseases: Cross-border recruitment challenges due to small patient populations.
Decentralized Trials: Diverging acceptance of telemedicine and direct-to-patient models in the EU and UK.
Oncology: Parallel submissions complicate large-scale Phase III cancer trials.

Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Informed Consent Challenges in Rural India

Posted on digi By digi

India’s clinical trial regulations have progressively strengthened ethical protections for participants, especially in underserved populations. The New Drugs and Clinical Trials Rules (NDCTR), 2019 mandate stringent requirements for the informed consent process and documentation. Additionally, Rule 25 of the NDCTR outlines responsibilities for investigators and ethics committees in obtaining consent.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Role of NIHR in UK Clinical Research

Posted on digi By digi

The NIHR is central to the UK’s clinical research ecosystem, enabling trials through funding, infrastructure, and workforce support. By engaging NIHR early and leveraging its networks, academic and industry sponsors can ensure efficient, transparent, and compliant trial delivery. NIHR’s integration with NHS priorities ensures research not only advances science but also directly benefits patients across the UK.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials